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Little is known about the longitudinal eﬀects of smoking cessation on sputum inﬂammatory cells. We aimed to investigate into
changes in sputum inﬂammatory cells and T-lymphocyte subpopulations after 6 and 12 months smoking cessation. Induced
sputum was obtained from 68 healthy smokers before and after 6 months (n = 21) and 1 year (n = 14) smoking cessation
and from ten healthy never-smokers. Inﬂammatory cells were identiﬁed by morphology and T-lymphocyte subpopulations by
ﬂow cytometry. Sputum macrophages were decreased after 12 months of smoking cessation in comparison to baseline, while
neutrophils increased. Moreover, CD8+ T-cells were decreased in smokers before smoking cessation compared to never-smokers
and increased in smokers after 6 months of smoking cessation in comparison to baseline, result that was maintained after 1 year
of smoking cessation. These novel ﬁndings indicate that smoking cessation can equilibrate certain inﬂammatory cells of smokers
with those of non smokers, within 6 months of smoking cessation.
Copyright © 2009 Izolde Bouloukaki et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Smoking is the main risk factor for the development of a
number of chronic lung diseases, such as chronic obstructive
pulmonary disease (COPD) and lung cancer, and scientiﬁc
evidence is conclusive of its role in the predisposition and
outcome of several others [1]. While as stated above, active
smoking is the main cause of lung cancer, smoking cessation
signiﬁcantly reduces the risk of lung cancer by 2-3 times at
10 years [2]. Moreover, sustained abstinence from smoking
decreases the rate of decline in lung function to the levels of
never-smokers and reduces the risk of developing clinically
signiﬁcantCOPD[2].Theseﬁndingssuggestthattheadverse
eﬀects of smoking in the lungs are partly reversed after
cessation.
The mechanisms of cigarette smoke-induced lung injury
have not been fully elucidated yet. However, it has been
suggested that the early inﬂammatory responses to cigarette
smoke are crucial to the development of subsequent tissue
damage and disease in susceptible individuals. Furthermore,
research has indicated that it may lead to a localised
reaction and sequestration of neutrophils in pulmonary
microvasculature and cause tissue damage through the
release of toxic and chemotactic mediators, and thus further
predispose to lung disease and inﬂammation [1–4]. Among
lymphocytes,circulatingCD4+ T-celllymphocyteshavebeen
suggested as target cells for smoking. In particular memory
CD4+ T-cell lymphocytes have been found to be selectively
and dose dependently increased by active smoking, which
is stimulated through the chronic procedure of habitual
smoking [5]. In support of this, the number of inﬂammatory
cells recovered by bronchoalveolar lavage ﬂuid (BALF) is
increased in smokers compared to never-smokers, primarily
d u et oa ni n c r e a s ei nB A L Fm a c r o p h a g e s[ 6–8]. Similarly to
BALF, there is a signiﬁcant increase in sputum and small
airway macrophages in smokers [9–12]. Moreover, several2 Mediators of Inﬂammation
reports have showed that neutrophils and lymphocytes are
increased in smokers [6–9, 12–16]. CD4+T-cells in BALF
of smokers have been reported to be decreased [15, 17]
and CD8+ T-cells to be increased, resulting in a markedly
decreased CD4+/CD8+ ratio compared to never-smokers
[18, 19]. Similarly, in the small airway submucosa, there is a
tr e ndt o war dad ecr easeinCD4 + T-cells,anincreaseinCD8+
T-cells and a signiﬁcant decrease in the CD4+/CD8+ T-cell
ratio in smokers as compared to non-smokers [13].
Much less is known about the eﬀects of smoking
cessation. Two relatively old cross-sectional studies found
no diﬀerences in inﬂammatory cells between smokers
and exsmokers [20, 21], while others showed that BALF
macrophage, but not neutrophil numbers are decreased
in exsmokers compared to smokers [22]. In addition, it
is worth noting that, in patients with COPD, one cross-
sectional study in induced sputum found no diﬀerences
in the cellular proﬁles and macrophage phenotypes when
comparing smokers with ex-smokers [23], possibly indi-
cating persistent inﬂammatory changes in the airways in
patients who are predisposed to COPD. Longitudinal studies
showed that BALF macrophages, neutrophils, lymphocytes
and sputum macrophages decrease to the levels of never-
smokers after smoking cessation [7, 24–26]. Reports on
sputum neutrophils are controversial, showing either a
decrease [25] or an increase [26]. There is only one longi-
tudinal study in “healthy” smokers assessing T-lymphocyte
subpopulationsinbronchialbiopsiesandthisstudyfoundno
diﬀerence in CD8+ and CD4+ T-lymphocytes after smoking
cessation [26]. No longitudinal studies have been reported
the eﬀect of smoking cessation on sputum T-lymphocyte
subpopulations in “healthy” smokers. We have conducted
a longitudinal study to examine whether changes in T
lymphocyte subpopulations and airway inﬂammatory cells
are reversed after a period of 6 months and 12 months
smoking cessation in “healthy” smokers.
2.MaterialsandMethods
2.1. Subjects. In the University Hospital of Heraklion, Crete,
induced sputum was obtained from 68 smokers recruited
from the smoking cessation clinic, before their entrance
into the smoking cessation protocol. All subjects provided
written informed consent and ethical approval was provided
by the University Hospitals Ethics Committee. Following
enrollment, all smokers participated in the same behavioural
therapy program and according to their degree of depen-
dence (Fagerstrom test) they received nicotine replacement
therapy and/or bupropion as part of their smoking cessation
treatment. Ten never-smokers were recruited by advertise-
ment and were the control subjects. All subjects were free
of any respiratory tract infections at the time of the study
or during the month preceding the study and at the follow-
up at 6 and 12 months. Subjects did not suﬀer from any
disease and did not receive any medication at the time of the
ﬁrst visit, while none had symptoms of chronic bronchitis.
Furthermore, baseline lung functional tests were within
the normal range and their chest radiograph was normal.
The participating subjects’ characteristics are depicted in
Table 1.
2.2. Sputum Collection, Induction and Flow Cytometry. Spu-
tum specimens were successfully collected at baseline in all
10 controls and 68 smokers, while suﬃc i e n ts p u t u mo fg o o d
quality was produced by 16 of the 21 successful quitters at
baseline after 6 months of follow-up, in 18 out of 21 who
had not relapsed (86% collection rate) and after 12 months
of smoking cessation in 9 out of 14 quitters (65% collection
rate).Duringeachfollow-up,conﬁrmationofsmokingstatus
was assessed both by exhaled CO and urine cotinine levels.
The progress of smoking cessation and sputum collection is
depicted in Figure 1.
Sputum was induced and processed as previously
describedin[27].Subjectsinhaledhypertonicsalineforthree
ten-minute sessions. The concentration of the inhaled saline
was consecutively increased in each session from 3% to 4%
andto5%.Alwaysbetweensessionstheinhalationprocedure
was interrupted and the subjects were asked to blow their
nose, rinse their mouth, and try to expectorate sputum into
a sterilized box. By this way saliva contamination of the
sample was minimized and the percentage of squamous cells
in the sample was decreased. Sputum was processed within
the next 30 minutes or no more than two hours, with the
sample always kept in ice. The volume of the sputum was
measuredandsputumsampleswithavolumeofatleast2mL
are reputed to be suﬃcient. The more viscid proportions of
thesputum(plugs)wereselectedandweighed.Dithiothreitol
(Calbiochem, Darmstadt, Germany) was added, followed by
phosphate buﬀersaline (PBS).Then, the mixture wasﬁltered
and centrifuged. The cell pellet was resuspended with PBS, a
total cell count of the sample was performed, and viability
was tested by means of trypan blue exclusion method.
If cell viability was less than 50% and/or squamous cell
contaminationmorethan20%,thesamplewasnotprocessed
further. Sputum cytospin slides were stained using May-
Grunwald Giemsa for diﬀerential cell count. Cell counting
was performed by one investigator (IB), blind to the origin
of the samples. At least 400 cells were counted. Cytospins
with <50% of squamous cells and >400 nonsquamous cells
werequaliﬁedasofgoodquality.Celldiﬀerentialcountswere
expressed as % of total sputum nonsquamous cells.
Approximately 106 sputum white cells were labelled for
ﬂow cytometry with monoclonal antibodies raised in mice
against human (all from Immunotech; Marseille, France):
phycoerythrin-cyanine (PECy-5) conjugated anti-CD8, ﬂu-
orescein isothiocyanate (FITC) conjugated anti-CD4, and
phycoerythrin (PE) conjugated anti-CD45 for 30 minutes at
4–8◦C or with isotype matched controls for 30 minutes at
4–8◦C. An ELITE COULTER cytometer was used. Data were
acquired in list mode and analyzed using Epics Elite. The
following gating strategy was applied: ﬁrst dead cells, debris
and epithelial cells were excluded on an SS-CD45 scatter
plot, then lymphocytes were gated on an FS-SS scatter plot
based on their size and granularity properties. Finally CD4
and CD8 positive cells were enumerated and expressed as
percentage of % sputum lymphocytes on a CD4/CD8 scatter
plot (Figure 2). Some samples were not suﬃcient enoughMediators of Inﬂammation 3
Table 1: Subject characteristics.
Smokers Nonsmokers
(controls)
P-value∗
Total Successful quitters
at 6 months
Nonquitters
N 68 21 47 10 N/A
Sex, M/F 59/9 19/2 40/7 8/2 P = .6
Age, (in years) 49 ±8 49 ±7 49 ±9 33 ±9 P = .002
Smoking (pack-years) 57 ±18 53 ±15 59 ±19 N/A N/A
FEV1, %pred Postbronchod. 105 ±12 109 ±13 104 ±11 116 ±13 P = .2
ΔFEV1 % pred 2.1 ±1.8 2.4 ±2.3 1.9 ±2.2 1.9 ±1.4 P = .16
Fagerstrom Score 8 ±1 7 ±1 8 ±1 N/A N/A
Data are presented as mean ± SD, or in absolute numbers, N/A: non applicable, FEV1: forced expiratory volume in one second; ΔFEV1: change in FEV1 after
bronchodilation.
∗P-value between controls and successful quitters.
Baseline
6m o n t h s
follow-up
1y e a r
follow-up
68 participants
at baseline
21 participants
remained abstinent
14 participants
remained abstinent
51 sputum samples
were eligible
17 sputum samples
were insuﬃcient
47 participants
dropped out
18 sputum samples
were eligible
3 sputum samples
were insuﬃcient
7 participants
dropped out
9 sputum samples
were eligible
5 sputum samples
were insuﬃcient
Figure 1: Flowchart of participation, smoking cessation and sputum quality.
(<106 sputum white cells) to be labelled for ﬂow cytometry
and this accounts for the occasional missed cases in some cell
counts (Figure 1).
2.3.StatisticalAnalysis. NormalitywastestedbytheShapiro-
Wilk test. Variables were nonnormally distributed. In the
groupofsubjectswhosuccessfullymanagedtoquitsmoking,
diﬀerences in smokers before and after 6 and 12 months
of smoking cessation were tested using the Friedman test
followed by the Wilcoxon Signed Ranks test to see pairwise
diﬀerences. Diﬀerences between smokers and the control
group were tested using the Mann-Whitney U test. The
software StatsDirect (Camcode Cambridge, UK) was used.
Probability values of <.05 were considered as statistically
signiﬁcant.
3. Results
Sputum characteristics in smokers both before and after
smoking cessation as also in the control population are4 Mediators of Inﬂammation
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Figure 2: Example of a ﬂow cytometric analysis with dot plots and histograms from a representative sample (from one subject). First,
epithelial cells were excluded from the analysis by gating on all CD45+ Fleukocytes (plot (a)). Then lymphocytes were gated by morphology
on an FS/SS plot (plot (b)). Finally, CD8+ and CD4+ lymphocytes were gated (plot (c)). Staining of isotype control antibodies is also shown
(plot (d)). PE: phycoerythrin, PC-5: phycoerythrin-cyanine, FITC: ﬂuorescein isothiocyanate.
Table 2: Sputum diﬀerential cell counts and lymphocyte subpopulations.
Smokers Controls
Total baseline Successful quitters Successful quitters Successful quitters (n = 10)
(n = 5 1 ) b a s e l i n e 6m o n t h s 1 2m o n t h s
(n = 16) (n = 18) (n = 9)
Weight, gr 1.2 (0.08–4.3) 1.4 (0.3–3.5) 0.89 (0.05–3.45) 1.08 (0.31–3.18) 1.41 (0.35–5.04)
TCC, ×106 cells 2.78 (0.06–13.2) 2.5 (0.1–11.2) 4.02 (0.59–11.8) 3.85 (0.47–19.6) 5.29 (1.16–7.00)
TCC/gr 2.27 (0.03–13.4) 1.6 (0.03–11.6) 4.78 (0.49–11.8) 2.86 (0.51–46.67) 2.18 (0.68–6.71)
Viability % 80.42 (50–98.6) 80.4 (50.6–96.9) 92.62 (50–99.37) 89.16 (70.37–98.53) 84.71 (67.01–98.79)
SQUAM 10 (0.01–49.9) 10.6 (0.01–43.7) 6.4 (0–20) 5 (0.49–39) 10.78 (2.31–48.5)
NEUTR % 55.6 (3.3–87.3) 48.8 (17.7–80) 55.3 (17–88) 61 (3.6–84.8)∗ 40.5 (3.6–94)
MACRO % 40.6 (12.3–94) 49.1 (20–80.3) 41.8 (11.2–82.2) 34.5 (14.5–57.3) 55 (5.4–94)
LYMPHO % 0.12 (0–6.2) 0.1 (0–6.2.7) 0.25 (0–1.5) 0.5 (0–1.6) 0.55 (0–4.1)
EOS % 0 (0–3.6) 0 (0–0) 0 (0–0) 0 (0–7) 0 (0–0.5)
CD4+% 59 (20–84) 58.5 (24–78.4) 54.7 (32.5–71) 40.2 (30.6–62) 53 (32–63)
CD8+% 13.9 (4–56) 13.6 (5–56) 24 (15–42)∗ 25.3 (12.5–46.6)∗ 22.3(16–49) †
CD4+/CD8+ ratio 3.8 (0.4–16.2) 3.7 (0.4–12.9) 2.3 (1.1–4.7)∗ 1.9 (0.9–4.8)∗ 2.3(0.9–3.2) †
TCC: total cell count, SQUAM: squamous cells, NEUTR: neutrophils, MACRO: macrophages, LYMPHO: lymphocytes, EOS: eosinophils.
Data are presented as median (range). Squamous cells are expressed as the percentage of all cells, diﬀerential cell counts are presented % of total sputum
nonsquamous cells, lymphocyte subpopulations are presented % of total sputum lymphocytes.
∗P <. 05 versus successful quitters at baseline, †P <. 05 between controls and successful quitters at baseline.
presented in Table 2. As depicted the general characteristics
of the samples (i.e., weight, total cell count, total cell count
per gram, and sample viability) remained the same during
the whole study, regardless of sampling time and subgroup.
Moreover when comparing the samples of smokers at
baseline with those of nonsmokers, the latter were found
to have a higher percentage of sputum CD8+ lymphocyte
subpopulations and subsequently a lower CD4+/CD8+ ratio
(22.3 versus 13.9, P<. 05 and 2.3 versus 3.8, P<. 05,
resp.). The percentages of inﬂammatory cells (neutrophils,
macrophages) in the sputum was not found to diﬀer
between smokers and nonsmokers at baseline, and was not
found to be altered in smokers after 6 months of smoking
cessation. However, after 12 months of smoking cessation,
the percentage of neutrophils was higher (61 versus 55,
P<. 05) and the percentage of macrophages was lower
(34.5 versus 40.6, P<. 05) when compared to baseline
measurements.
Furthermore, as depicted in Figure 3, the percentage of
CD4+ T-lymphocytes did not diﬀer between smokers and6 Mediators of Inﬂammation
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Figure 3: Percentage of sputum CD4
+ T-cells (% sputum lympho-
cytes) in “healthy” smokers before smoking cessation (n = 16), after
6monthsofsmokingcessation (n =18), andafter 1year ofsmoking
cessation (n = 9). Results from 10 never-smokers (controls) are also
presented.
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Figure 4: Percentage of sputum CD8
+ T-cells (% sputum lympho-
cytes) in “healthy” smokers before smoking cessation (n = 16), after
6monthsofsmokingcessation (n =18), andafter 1year ofsmoking
cessation (n = 9). Results from 10 controls are also presented.
controls. However, the number of CD4+ T-cells (expressed
as a % of sputum lymphocytes) was not found to alter
after cessation both after 6-month and 1-year follow-up.
As noted above, a statistically signiﬁcant lower percentage
of CD8+ T-cells was observed in smokers in comparison
to controls. Moreover, the percentage of CD8+ T-cells
increased after 6 months of smoking cessation in quitters,
and reached the controls’ levels (Figure 4). During the
months between month 6 and year 1 of follow-up, the
percentage of CD8+ T-cells did not signiﬁcantly diﬀer. When
theCD4+/CD8+ ratiowascalculated,itwasfoundtobemore
increased in smokers than in controls at baseline (Figure 5).
Furthermore, it signiﬁcantly decreased within 6 months of
smoking, while as with the percentage of CD8+ cells, the
CD4+/CD8+ ratio was not found to change after month 6 of
cessation.
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Figure 5: Percentage of sputum CD4
+/CD8
+ T-cells (% sputum
lymphocytes) in “healthy” smokers before smoking cessation (n =
16), after 6 months of smoking cessation (n = 18), and after 1 year
of smoking cessation (n = 9). Results from 10 controls are also
presented.
4. Discussion
Our results indicated that smokers showed a lower percent-
age of CD8+ T-cells and an increase in the CD4+/CD8+ ratio
compared to never-smokers at baseline. What is of interest
though is that a signiﬁcant increase in CD8+ T-lymphocytes
and a decrease in the CD4+/CD8+ ratio were observed
within 6 months of smoking cessation which reached the
levels of controls. As, traditionally, the major activity of
CD8+ T lymphocytes has been considered the facilitation
of the rapid resolution of acute viral infections, the lower
percentage of CD8+ T-cells suggests that smokers have a
deﬁcit in cell-mediated immunity in the lung, a site critical
in the ﬁrst-line defence against infection, and may explain
the increased susceptibility of smokers for viral infections.
Furthermore, previously our group has demonstrated that
the expression of sputum dendritic cells maturation markers
in smokers is decreased, which may signiﬁcantly aﬀect
the ability of dendritic cells to induce eﬀective immune
responses, altering the lymphocyte subset population and
therefore render smokers more susceptible to respiratory
tract infections [28]. Moreover, after 12 months smoking
cessation sputum macrophages decreased and neutrophils
signiﬁcantly increased among those who had quit.
To the best of our knowledge there is very limited
evidence that has assessed the alteration of T-lymphocyte
subpopulations after smoking cessation. The present study
is one of the ﬁrst longitudinal studies that investigate the
eﬀectofsmoking cessationonT-lymphocytesubpopulations
in induced sputum of smokers with no concurrent disease or
lung function impairment.
Our ﬁndings seem to contradict the previously reported
increase of CD8+ T-cells and the decrease in CD4+/CD8+
ratio in smokers compared with never-smokers in BALF
and bronchial biopsies [13, 17–19]. Furthermore, a previous
study on bronchial biopsies showed no diﬀerence in CD8+Mediators of Inﬂammation 7
andCD4+ T-lymphocytesbeforeandaftersmokingcessation
[26]. These discrepancies could reﬂect the diﬀerent inﬂam-
matory microenvironment between airway lumen sampled
by sputum and airway epithelium and mucosa sampled
by bronchial biopsies [29]. Another possible explanation is
that smoking suppresses the trans-epithelial migration of
CD8+ lymphocytes, increasing their number in the large
airway wall, while reducing their number in the airway
lumen [30]. Therefore, it may be that in smokers, due to
the abnormal trans-epithelial migration mechanism, CD8+
T-cells are increased in bronchial biopsies and decreased
in the airway lumen, sampled by induced sputum. After
smokingcessation,thetrans-epithelialmigrationofCD8+ T-
cells is restored and therefore higher numbers are detected in
induced sputum [30].
The present study did not show any diﬀerence in sputum
CD4+ T-cell numbers between smokers and never-smokers,
as previously shown in [8, 16, 19, 26, 31]. Furthermore,
no signiﬁcant changes in the percentages of inﬂammatory
cells (neutrophis, macrophages) in sputum were found in
smokerscomparedtonever-smokers.However,inagreement
to the previous studies, the percentage of macrophages
in sputum decreased after smoking cessation [7, 22, 24–
27]. Additionally, the percentage of neutrophils signiﬁcantly
increased at 12 months smoking cessation, which is in
agreement with a previous study in sputum [26]. It is
possible that this noted increase in the percentages of
sputum neutrophils could be due to increased apoptosis
and transepithelial migration and may actually represent
a protective mechanism to remove activated neutrophils
from airway wall into the airway lumen [29]. However,
the scientiﬁc evidence is inconclusive as other studies have
shown that BALF neutrophils decrease to the levels of never-
smokers at 6, 9 and 15 months after smoking cessation [7],
while sputum neutrophils decrease at 12 months of smoking
cessation [25].
The present study although novel and longitudinal, and
therefore in a position to investigate into cause and eﬀect
did have some limitations that deserve comment. First,
sputum samples cells primarily come from the lumen of
the central airways and sputum changes in inﬂammatory
cells and T-cells do not necessarily reﬂect changes in airway
wall. However, common methods to study tissue, such as
the examination of bronchial biopsies or surgical specimens
cannot be easily applied on longitudinal studies. Second,
as sputum has to be homogenized before ﬂow cytometry,
a possible eﬀect of dithiothreitol (DTT) treatment on
lymphocyte antigens has to be considered. The reducing
agentDTTcouldhavealteredtheCD8antigenandinterfered
with the recognition of the antibody. In the present study
a detailed analysis of the eﬀects of DTT on the appropriate
surface markers was not performed. However, Loppow et
al. investigated peripheral blood leukocytes as a model for
induced sputum cells and showed that the ﬂuorescence
intensity of CD8 was not altered by DTT, while there was
statistically signiﬁcant (P<. 001), although small, changes
in the percentages of CD8 positive lymphocytes. The authors
concluded that comparability between samples concerning
lymphocyte surface markers is preserved, suggesting that
treatment of sputum samples with dithiothreitol does not
invalidate the immunocytochemical analysis of lymphocytes
[32]. Moreover, the mean age in the smokers’ group was
greater than in the control group and it could be argued that
diﬀerences in lymphocyte subpopulations between smokers
and never-smokers are due to age diﬀerence. However, it has
been shown that age predominately reduces the numbers of
CD4+ T-cells, while we found only a diﬀerence in CD8+ T-
cells [33, 34]. Moreover, all our subjects were below 65 years
and changes in T-cells have been mostly reported in subjects
above that age. Furthermore, it is possible that gender factors
could play a role, as the data presented were mainly based
on that of male subjects. Another limitation of the study was
the relatively small number of subjects, especially successful
quittersafteroneyearofsmokingcessation.Thisisduetothe
increased relapse rate of smoking within 1 year. Taking the
above into account, further studies, using a larger number of
smokers, are needed to investigate the exact mechanism.
5. Conclusions
Conclusively, our results indicate that smoking cessation
increases the percentage of CD8+ T-cells and decreases the
CD4+/CD8+ ratio within 6 months of smoking cessation to
that of the level of never-smokers, and is retained at that level
among those abstinent at 12 months. These results indicate
that some aspects of inﬂammation and immunological
processes taking place in the airways of smokers with no
existing lung impairment or concurrent respiratory disease
can be reversed in those subjects who successfully quit
smoking.
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